Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1713540 | 0.85 | CYP1A2 (0.58) | KEAP1KDM4EMAPTALDH1A1HPGD | |
| SCHEMBL30548341 | 0.85 | CYP1A2 (0.58) | KEAP1KDM4EMAPTALDH1A1HPGD | |
| SCHEMBL15962073 | 0.83 | MMP2 (0.53) | KEAP1KDM4EKMT2AGFERRXFP1 | |
| SCHEMBL30325610 | 0.82 | DGAT1 (0.44) | KEAP1KDM4EKMT2AGFERRXFP1 | |
| SCHEMBL9344625 | 0.81 | KEAP1 (0.50) | KEAP1KDM4EKMT2AGFERRXFP1 | |
| SCHEMBL1020183 | 0.81 | KEAP1 (0.50) | KEAP1KDM4EKMT2AGFERRXFP1 | |
| SCHEMBL17049159 | 0.81 | KDM4E (0.50) | KEAP1KDM4EKMT2AGFERRXFP1 | |
| SCHEMBL5517947 | 0.81 | KEAP1 (0.50) | KEAP1KDM4EKMT2AGFERRXFP1 | |
| SCHEMBL1020878 | 0.81 | KEAP1 (0.50) | KEAP1KDM4EKMT2AGFERRXFP1 | |
| SCHEMBL31227767 | 0.80 | MMP2 (0.61) | KEAP1KDM4EKMT2AGFERRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228511-A1 | SUBSTITUTED FUSED AZINES AS KRAS G12D INHIBITORS | ELI LILLY AND COMPANY | 2024-07-11 | — | — | US | disclosed |
| US-20240228511-A1 | SUBSTITUTED FUSED AZINES AS KRAS G12D INHIBITORS | ELI LILLY AND COMPANY | 2024-07-11 | — | — | US | disclosed |
| CN-117500799-A | Substituted fused azines as KRAS G12D inhibitors | 伊莱利利公司 | 2024-02-02 | — | — | CN | disclosed |
| US-20240025916-A1 | KRAS G12C INHIBITORS | ELI LILLY AND COMPANY | 2024-01-25 | — | — | US | disclosed |
| US-20240025916-A1 | KRAS G12C INHIBITORS | ELI LILLY AND COMPANY | 2024-01-25 | — | — | US | disclosed |
| US-20230339968-A1 | KRAS Gl2C INHIBITORS | ELI LILLY AND COMPANY | 2023-10-26 | — | — | US | disclosed |
| US-20230339968-A1 | KRAS Gl2C INHIBITORS | ELI LILLY AND COMPANY | 2023-10-26 | — | — | US | disclosed |
| EP-4255912-A1 | TRICYCLIC KRAS G12C INHIBITORS | Eli Lilly and Company (US) | 2023-10-11 | — | — | EP | disclosed |
| US-11731984-B2 | KRas G12C inhibitors | ELI LILLY AND COMPANY (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731984-B2 | KRas G12C inhibitors | ELI LILLY AND COMPANY (US) | 2023-08-22 | — | — | US | disclosed |
| EP-2190827-B1 | N-BENZYL-N'-ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS | ORGANON NV (NL) | 2011-01-12 | — | — | EP | disclosed |
| WO-2010118986-A1 | FLUORO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK3 INHIBITORS | CELLZOME LIMITED (GB) | 2010-10-21 | — | — | WO | disclosed |
| EP-2190827-A1 | N-BENZYL, N' -ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS | N.V. Organon (NL) | 2010-06-02 | — | — | EP | disclosed |
| US-20090318408-A1 | HALO-SUBSTITUTED PYRIMIDODIAZEPINES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-24 | — | — | US | disclosed |
| WO-2009153197-A1 | HALO-SUBSTITUTED PYRIMIDODIAZEPINES AS PLKL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-23 | — | — | WO | disclosed |
| US-20090264416-A1 | N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES | N.V. ORGANON AND PHARMACOPEIA, INC. | 2009-10-22 | — | — | US | disclosed |
| WO-2009024550-A1 | N-BENZYL, N' -ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS | N.V. ORGANON (NL) | 2009-02-26 | — | — | WO | disclosed |
| EP-0882725-B1 | QUINOLONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2002-12-18 | — | — | EP | disclosed |
| US-6025370-A | METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS | TOYAMA CHEMICAL CO., LTD. (JP) | 2000-02-15 | — | — | US | disclosed |
| EP-0882725-A1 | QUINOLONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339968-A1 | KRAS Gl2C INHIBITORS | KRAS, NRAS, GLS2 | KEAP1 160/4885KDM4E 2605/4885KMT2A 558/4885 |
| US-20090264416-A1 | N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES | NPC1L1, NPC1, ABCB11 | KEAP1 932/4885KDM4E 3490/4885KMT2A 4268/4885 |
| US-11731984-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | KEAP1 143/4885KDM4E 2846/4885KMT2A 1197/4885 |
| US-20240025916-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | KEAP1 250/4885KDM4E 3391/4885KMT2A 1524/4885 |
| US-20240228511-A1 | SUBSTITUTED FUSED AZINES AS KRAS G12D INHIBITORS | KRAS, NRAS, TP53 | KEAP1 457/4885KDM4E 1034/4885KMT2A 413/4885 |
| US-20090318408-A1 | HALO-SUBSTITUTED PYRIMIDODIAZEPINES | PLK1, CCNI, CDK1 | KEAP1 355/4885KDM4E 2536/4885KMT2A 663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.